Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Genetically determined neuropathies

M M Reilly1

  • 1National Hospital for Neurology and Neurosurgery, London, UK.

Journal of Neurology
|February 11, 1998
PubMed
Summary
This summary is machine-generated.

Recent advances reveal genetic defects in hereditary neuropathies, improving diagnosis and genetic counseling. Transthyretin-related familial amyloid polyneuropathy now has liver transplantation as a definitive treatment.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Patient-reported disease burden in the Accelerate Clinical Trials in Charcot-Marie-Tooth Disease Study.

Journal of the peripheral nervous system : JPNS·2024
Same author

The integrated stress response contributes to tRNA synthetase-associated peripheral neuropathy.

Science (New York, N.Y.)·2021
Same author

Are we prepared for clinical trials in Charcot-Marie-Tooth disease?

Brain research·2020
Same author

Routine blood monitoring in maintenance immunoglobulin treatment of inflammatory neuropathy: Is it clinically relevant?

Journal of the neurological sciences·2019
Same author

Gene replacement therapy after neuropathy onset provides therapeutic benefit in a model of CMT1X.

Human molecular genetics·2019
Same author

Spinal Stenosis in Familial Transthyretin Amyloidosis.

Journal of neuromuscular diseases·2019
Same journal

Genome-wide spectrum of coding DNA variations in Indian patients with amyotrophic lateral sclerosis.

Journal of neurology·2026
Same journal

Genetic spectrum and clinical features of PMP22 point mutations in Japanese Charcot-Marie-Tooth disease.

Journal of neurology·2026
Same journal

Migraine and auditory dysfunction: beyond comorbidity.

Journal of neurology·2026
Same journal

Efficacy and safety of ofatumumab in participants with relapsing multiple sclerosis and breakthrough disease on oral fingolimod or fumarates: results from the ARTIOS study.

Journal of neurology·2026
Same journal

Long-term persistence, safety and effectiveness of nusinersen in spinal muscular atrophy: a population-based study.

Journal of neurology·2026
Same journal

Quantification of amyotrophic lateral sclerosis (ALS) disease accumulation with T1-weighted high-resolution magnetic resonance imaging: validation in an independent cohort.

Journal of neurology·2026
See all related articles

Area of Science:

  • Neurology
  • Genetics
  • Molecular Biology

Background:

  • Significant progress has been made in understanding genetically determined neuropathies.
  • Genetic defects are identified for many demyelinating hereditary motor and sensory neuropathies (HMSN).
  • Linkage data is emerging for axonal forms of HMSN.

Purpose of the Study:

  • To review recent advances in the molecular genetics of hereditary neuropathies.
  • To discuss implications for diagnosis and genetic counseling.
  • To highlight challenges in classifying hereditary motor and sensory neuropathies.

Main Methods:

  • Literature review focusing on molecular genetics.
  • Analysis of genetic defects in hereditary neuropathies.
  • Examination of diagnostic and counseling implications.

Related Experiment Videos

Main Results:

  • Genetic underpinnings of numerous demyelinating HMSN identified.
  • Genetic defect known for most familial amyloid polyneuropathy (FAP) cases.
  • Liver transplantation established as a treatment for transthyretin-related FAP.

Conclusions:

  • Advances in molecular genetics are transforming the diagnosis and management of hereditary neuropathies.
  • Genetic insights offer new avenues for counseling and treatment.
  • Classification of HMSN remains complex despite genetic discoveries.